The objective of the Fund is to provide capital growth.
Name | % Net Assets |
---|---|
Royal Dutch Shell 'B' | 5.2% |
BP | 4.9% |
British American Tobacco | 4.6% |
HSBC | 4.5% |
Vodafone | 3.8% |
GlaxoSmithKline | 3.7% |
AstraZeneca | 3.6% |
Centrica | 3.2% |
Aviva | 3.0% |
Standard Chartered | 2.9% |
Key | % Net Assets |
---|---|
Royal Dutch Shell 'B' | 5.2% |
BP | 4.9% |
British American Tobacco | 4.6% |
HSBC | 4.5% |
Other | 80.8% |
Date | 23-Jun-2023 |
---|---|
NAV | 241.38p |
Currency | GBP |
Change | -1.20p |
% | -0.49% |
YTD change | 241.38p |
YTD % | n/a |
Fund Inception | n/a |
---|---|
Fund Manager | Pan European Equities Team |
TER | - |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.75% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.13 |
You are here: research